All lobbying filings

Bridgebio Pharma, Inc.

Bridgebio Pharma, Inc. filed a Q1 report for Bridgebio Pharma, Inc. on April 18, 2025.

Lobbying for Bridgebio Pharma, Inc. · Biotech company

As filed: BRIDGEBIO PHARMA, INC. for BRIDGEBIO PHARMA, INC.

All filings by Bridgebio Pharma, Inc. · Everything Bridgebio Pharma, Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 18, 2025

Expenses

$320,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

Give Kids a Chance Act of 2025 - H.R. 1262; S. 932 Orphan drug policies Scientific EXPERT Act of 2024 - H.R.1532; S. 822 Cameron's Law - H.R. 1414 FY25 Full Year Continuing Appropriations and Extensions Act - H.R. 1968

Bills named in this filing 6

H.R. 1262
Mikaela Naylon Give Kids a Chance Act
S. 932
Give Kids a Chance Act of 2025
H.R. 1532
Scientific EXPERT Act of 2025
S. 822
Scientific EXPERT Act of 2025
H.R. 1414
Cameron’s Law
H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.